PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights • Key buying criteria PART 05: Disease overview • Introduction • Risk factors • Diagnosis • Management • Epidemiology • Economic burden PART 06: Insulin: An overview • Product portfolio • Global human insulin market PART 07: Pipeline analysis • Faster-acting insulin aspart (NN1218) • Farxiga/Forxiga • SAR342434 • NN9211 • LY2605541 • Sotagliflozin • MK-1293 • PRL001 • Otelixizumab PART 08: Reimbursement scenario in US PART 09: Market landscape • Global diabetes drugs market • Global type 1 diabetes drugs market • Five forces analysis PART 10: Market segmentation by drug class • Insulin • Others PART 11: Geographical segmentation • Type 1 diabetes drugs market in Americas • Type 1 diabetes drugs market in EMEA • Type 1 diabetes drugs market in APAC PART 12: Market drivers • Increase in prevalence of type 1 diabetes • Advances in insulin delivery technology • Rise in price of insulin drugs • Stringent regulatory conditions for biosimilar drugs • Promising drug pipeline PART 13: Impact of drivers PART 14: Market challenges • Side effects of current therapies • Fierce market competition • Poor storage conditions and distribution policies for insulin • Gap in nation-level diabetes management plans • Rising concerns in scientific community PART 15: Impact of drivers and challenges PART 16: Market trends • Development of drugs with novel mechanisms • Awareness programs and initiatives • Focus on emerging markets • Increase in academia-industry collaboration PART 17: Vendor landscape • Competitive scenario • Market analysis 2015 • Novo Nordisk • Sanofi • Eli Lilly • Other prominent vendors PART 18: Appendix • List of abbreviations PART 19: Explore Technavio List of Exhibits  Exhibit 01: Product offerings Exhibit 02: Key buying criteria for type 1 diabetes drugs Exhibit 03: Diagnostic test for diabetes based on blood sugar levels Exhibit 04: Diagnostic test for diabetes based on glycated hemoglobin levels Exhibit 05: Global human insulin market 2015-2020 ($ billions) Exhibit 06: Pipeline portfolio: Global type 1 diabetes drugs market Exhibit 07: Global diabetes drugs market by type of disease prevalence 2015 Exhibit 08: Top-selling diabetes drugs based on sales 2014 ($ billions) Exhibit 09: Market share of global diabetes drugs in global pharmaceutical drugs market 2015 Exhibit 10: Global diabetes drugs market 2015-2020 ($ billions) Exhibit 11: Market share analysis of vendors in global diabetes drugs market 2015 Exhibit 12: Global type 1 diabetes drugs market 2015-2020 ($ billions) Exhibit 13: Five forces analysis Exhibit 14: Segmentation of type 1 diabetes drugs market by drug class Exhibit 15: Estimated market share of global type 1 diabetes drugs market by drug class 2020 Exhibit 16: Segmentation of global type 1 diabetes drugs market based on geography 2015 Exhibit 17: Type 1 diabetes drugs market revenue by geography 2015-2020 ($ billions) Exhibit 18: Global type 1 diabetes drugs market by geography 2015-2020 Exhibit 19: Type 1 diabetes drugs market in Americas 2015-2020 ($ billions) Exhibit 20: Type 1 diabetes drugs market in EMEA 2015-2020 ($ billions) Exhibit 21: Type 1 diabetes drugs market in APAC 2015-2020 ($ billions) Exhibit 22: Global type 1 diabetes drugs market: YoY growth and revenue based on geography 2015-2020 Exhibit 23: Impact of drivers Exhibit 24: Impact of drivers and challenges Exhibit 25: Revenues from sales of major products in type 1 diabetes market 2012-2014 ($ billions) Exhibit 26: Novo Nordisk: Business segmentation by revenue 2015 Exhibit 27: Novo Nordisk: R&D expenditure 2015 Exhibit 28: Novo Nordisk: YoY revenue and growth rate generated from net product sales of human insulins 2012-2015 ($ billions) Exhibit 29: Novo Nordisk: YoY revenue and growth rate generated from net product sales of Levemir 2012-2015 ($ billions) Exhibit 30: Novo Nordisk: YoY revenue and growth rate of NovoRapid/NovoLog 2012-2015 ($ billions) Exhibit 31: Novo Nordisk: Geographical split of revenues of NovoRapid/NovoLog, 2015 Exhibit 32: Novo Nordisk: YoY revenue and growth rate of NovoMix/NovoLog Mix 2012-2015 ($ billions) Exhibit 33: Novo Nordisk: Geographical split of revenues of NovoMix/NovoLog Mix, 2015 Exhibit 34: Novo Nordisk: YoY revenue and growth rate generated from net product sales of new-generation insulins 2013-2015 ($ millions) Exhibit 35: Novo Nordisk: Key takeaways Exhibit 36: Sanofi: Business segmentation by revenue 2015 Exhibit 37: Sanofi: YoY revenue and growth rate of Lantus 2013-2015 ($ billions) Exhibit 38: Sanofi: Lantus geographical segmentation by revenue 2015 Exhibit 39: Sanofi: YoY revenue and growth rate of Apidra 2013-2015 ($ millions) Exhibit 40: Sanofi: YoY revenue and growth rate of Insuman 2013-2015 ($ millions) Exhibit 41: Sanofi: Key takeaways Exhibit 42: Eli Lilly: YoY revenue and growth rate of Humalog 2013-2015 ($ billions) Exhibit 43: Eli Lilly: YoY revenue and growth rate of Humulin 2013-2015 ($ billions) Exhibit 44: Eli Lilly: Key takeaways

Eli Lilly and Company, Novo Nordisk A/S, Sanofi SA, Adocia, Astellas Pharma, AstraZeneca, Baxalta, BHV Pharma, Biocon, Biodel, Boehringer Ingelheim, CureDM, Dance Biopharm, Diamyd Therapeutics AB, Diasome Pharmaceuticals, DiaVac, Exsulin, Gan & Lee Pharmaceuticals, Generex Biotechnology, GlaxoSmithKline, ILTOO Pharma, Intrexon, Islet Sciences, Kamada, Kotobuki Pharmaceutical, Lexicon Pharmaceuticals, Living Cell Technologie, MacroGenics, MannKind Pharmaceuticals, Merck, Merrion Pharmaceutical, Oramed Pharmaceuticals, Osiris Therapeutics, Perle Biosciences, Pfizer, REGiMMUNE, Strongbridge Biopharma, Toleranzia, Tolerio, Xeris Pharmaceuticals, XOMA.